Characteristics of study subjects
| Asthmatics(n = 14) | Controls(n = 9) | p value | |
|---|---|---|---|
| *Values are mean (SE). | |||
| †Treatments are short acting β2 agonist (SABA), inhaled corticosteroid (ICS), long acting β2 agonist (LABA), or oral prednisolone 20 mg/day (Pred). | |||
| GINA, Global Initiative for Asthma. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. | |||
| p values from one way analyses of variance tests are indicated. | |||
| Asthma severity | |||
| GINA 1 (n) | 2 | 0 | |
| GINA 2 (n) | 2 | 0 | |
| GINA 3 (n) | 2 | 0 | |
| GINA 4 (n) | 8 | 0 | |
| Asthma history (years)* | 25.8 (4.2) | 0.0 (0.0) | |
| Current treatment† | |||
| SABA (n) | 14 | 0 | |
| ICS (n) | 10 | 0 | |
| LABA (n) | 4 | 0 | |
| Pred (n) | 2 | 0 | |
| Sex (M/F) | 5/9 | 6/3 | |
| Age (years)* | 43.7 (4.7) | 47.8 (5.4) | 0.40 |
| Atopy | Yes | No | |
| FEV1 (%)* | 84.7 (7.2) | 95.1 (3.8) | 0.34 |
| FVC (%)* | 100.4 (5.6) | 96.6 (3.3) | 0.70 |